Barinthus Biotherapeutics Plc Stock Working Capital
| BRNS Stock | 0.95 0.02 2.06% |
Barinthus Biotherapeutics plc fundamentals help investors to digest information that contributes to Barinthus Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Barinthus Stock. The fundamental analysis module provides a way to measure Barinthus Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Barinthus Biotherapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 144.3 M | 134.5 M | |
| Change In Working Capital | 6.2 M | 6.5 M |
Barinthus | Working Capital |
Barinthus Biotherapeutics plc Company Working Capital Analysis
Barinthus Biotherapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Barinthus Biotherapeutics Working Capital | 144.31 M |
Most of Barinthus Biotherapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Barinthus Biotherapeutics plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Barinthus Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Barinthus Biotherapeutics is extremely important. It helps to project a fair market value of Barinthus Stock properly, considering its historical fundamentals such as Working Capital. Since Barinthus Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Barinthus Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Barinthus Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Barinthus Capital Lease Obligations
Capital Lease Obligations |
|
In accordance with the company's disclosures, Barinthus Biotherapeutics plc has a Working Capital of 144.31 M. This is 66.1% lower than that of the Biotechnology sector and 73.21% lower than that of the Health Care industry. The working capital for all United States stocks is 90.24% higher than that of the company.
Barinthus Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Barinthus Biotherapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Barinthus Biotherapeutics could also be used in its relative valuation, which is a method of valuing Barinthus Biotherapeutics by comparing valuation metrics of similar companies.Barinthus Biotherapeutics is currently under evaluation in working capital category among its peers.
Barinthus Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | (55.02 M) | ||||
| Shares Outstanding | 40.23 M | ||||
| Shares Owned By Insiders | 9.39 % | ||||
| Shares Owned By Institutions | 46.22 % | ||||
| Number Of Shares Shorted | 11.67 K | ||||
| Price To Book | 0.24 X | ||||
| Price To Sales | 2.57 X | ||||
| Revenue | 802 K | ||||
| Gross Profit | 44.7 M | ||||
| EBITDA | (74.81 M) | ||||
| Net Income | (73.45 M) | ||||
| Total Debt | 12.98 M | ||||
| Book Value Per Share | 4.03 X | ||||
| Cash Flow From Operations | (50.92 M) | ||||
| Short Ratio | 0.29 X | ||||
| Earnings Per Share | (1.49) X | ||||
| Target Price | 7.17 | ||||
| Number Of Employees | 130 | ||||
| Beta | -0.58 | ||||
| Market Capitalization | 38.41 M | ||||
| Total Asset | 214.51 M | ||||
| Retained Earnings | (176.59 M) | ||||
| Working Capital | 144.31 M | ||||
| Net Asset | 214.51 M |
About Barinthus Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Barinthus Biotherapeutics plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Barinthus Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Barinthus Biotherapeutics plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.